The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ICML 2019 | Cellular kinetics of CAR-T & prophylactic promise
Carl June, MD, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, discusses the expansion and durability of CAR T-cells following treatment, as well as speculating upon their future potential to even be given prior to disease in those at high risk. This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.
